Cutaneous Adnexal Adenocarcinoma: Genomic Analysis and Successful HER2-targeted Therapy of Metastatic Disease
DOI:
https://doi.org/10.2340/actadv.v103.9399Keywords:
adnexal adenocarcinoma, cutaneous adnexal adenocarcinoma, adnexal adenocarcinoma NOS, her2, whole genome sequencing, her-2 antibodiesAbstract
Abstract is missing (Short communication)
Downloads
References
De Iuliis F, Amoroso L, Taglieri L, Vendittozzi S, Blasi L, Salerno G, et al. Chemotherapy of rare skin adnexal tumors: a review of literature. Anticancer Res 2014; 34: 5263-5238
Swain SM, Miles D, Kim SB, Im YH, Im SA, Semiglazov V, et al. CLEOPATRA study group. Pertuzumab, trastuzumab, and docetaxel for HER2-positive metastatic breast cancer (CLEOPATRA): end-of-study results from a double-blind, randomised, placebo-controlled, phase 3 study. Lancet Oncol 2020; 21: 519-530.
https://doi.org/10.1016/S1470-2045(19)30863-0 DOI: https://doi.org/10.1016/S1470-2045(19)30863-0
Cavalieri S, Busico A, Capone I, Conca E, Dallera E, Quattrone P, et al. Identification of potentially druggable molecular alterations in skin adnexal malignancies. J Dermatol 2019; 46: 507-514.
https://doi.org/10.1111/1346-8138.14889 DOI: https://doi.org/10.1111/1346-8138.14889
Chang D, Shain AH. The landscape of driver mutations in cutaneous squamous cell carcinoma. NPJ Genom. Med 2021; 6: 61.
https://doi.org/10.1038/s41525-021-00226-4 DOI: https://doi.org/10.1038/s41525-021-00226-4
Bonilla X, Parmentier L, King B, Bezrukov F, Kaya G, Zoete V, et al. Genomic analysis identifies new drivers and progression pathways in skin basal cell carcinoma. Nat Genet 2016; 48: 398-406.
https://doi.org/10.1038/ng.3525 DOI: https://doi.org/10.1038/ng.3525
Meinhardt M, Krebs R, Anders A, Heinrich U, Tronnier H. Wavelength-dependent penetration depths of ultraviolet radiation in human skin. J Biomed Opt 2008; 13: 044030.
https://doi.org/10.1117/1.2957970 DOI: https://doi.org/10.1117/1.2957970
Brown TJ, Sher DJ, Nedzi LA, Hughes RS, Beg MS, Mull J, et al. Cutaneous adnexal adenocarcinoma with exquisite sensitivity to trastuzumab. Head Neck 2017; 39: E69-71.
https://doi.org/10.1002/hed.24682 DOI: https://doi.org/10.1002/hed.24682
Otsuka M, Yamasaki O, Kaji T, Shien T, Iwatsuki K. Metastatic cutaneous apocrine adenocarcinoma treated with a combination of pertuzumab-based targeted therapy and taxane chemotherapy: a case report. JAMA Dermatol 2016; 152: 111-113.
https://doi.org/10.1001/jamadermatol.2015.2507 DOI: https://doi.org/10.1001/jamadermatol.2015.2507
Published
How to Cite
License
Copyright (c) 2023 Yui Hirano-Lotman, Yoshihiro Ishida, Yuichiro Endo, Seishi Ogawa, Kenji Kabashima
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
All digitalized ActaDV contents is available freely online. The Society for Publication of Acta Dermato-Venereologica owns the copyright for all material published until volume 88 (2008) and as from volume 89 (2009) the journal has been published fully Open Access, meaning the authors retain copyright to their work.
Unless otherwise specified, all Open Access articles are published under CC-BY-NC licences, allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material for non-commercial purposes, provided proper attribution to the original work.
